$BIAFW News

Last published 2w ago

2w agoBIAF BIAFWbioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness MonthBusiness WireBenefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" EventIn recognition of National Lung Cancer Awareness Month, bioAffinity
4w agoBIAF BIAFWbioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026Business WireChief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss preliminary
1mo agoBIAF BIAFWbioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026Business WireFindings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets Company advances research and development in diagnostic tests for major lung
1mo agoBIAF BIAFWWallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireJERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a
1mo agoBIAF BIAFWbioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its
1mo agoBIAF BIAFWWallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireJERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a
1mo agoBIAF BIAFWbioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into
1mo agoBIAF BIAFWbioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built AlgorithmBusiness WireCompany’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia Patent strategy protects proprietary CyPath Lung flow cytometry+AI approach in international
1mo agoBIAF BIAFWbioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026Business WireNearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by nearly 50% bioAffinity Technologies, Inc. (NASDAQ:BIAF,
1mo agoBIAF BIAFWbioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICALBusiness WireCompanies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026bioAffinity engages GO2 for Lung Cancer network to broaden outreach to veterans at riskbioAffinity
1mo agoBIAF BIAFWbioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual ConferenceBusiness WirePresentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care NAVREF 2026 focuses on innovative research to improve healthcare for veterans bioAffinity Technologies, Inc. (NASDAQ:BIAF,
1mo agoBIAF BIAFWbioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer DiagnosticBusiness WireDual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide bioAffinity Technologies, Inc.
2mo agoBIAF BIAFWbioAffinity Technologies Regains Compliance with Nasdaq Listing RequirementsBusiness WireBIAF continues to be listed and traded on Nasdaq bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of
2mo agoBIAF BIAFWbioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced that President and CEO
2mo agoBIAF BIAFWbioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer SurvivorsBusiness WireMore than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance Noninvasive CyPath® Lung has the potential to complement imaging in monitoring for
2mo agoBIAF BIAFWbioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026Business WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse
2mo agoBIAF BIAFWbioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® LungBusiness WireNew partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity's commercial reach through
3mo agoBIAF BIAFWWallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq RulesPR NewswireJERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),
3mo agoBIAF BIAFWbioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq RulesBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement
3mo agoBIAF BIAFWWallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq RulesPR NewswireJERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF,
3mo agoBIAF BIAFWbioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq RulesBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with
3mo agoBIAF BIAFWbioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® LungBusiness WireCyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical trial Pipeline expands to include development of precision
3mo agoBIAF BIAFWbioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® LungBusiness WireComprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway Framework includes protocols for pulmonology, primary care and
3mo agoBIAF BIAFWbioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPDBusiness WireCollaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide Global asthma and COPD
4mo agoBIAF BIAFWbioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum ContinuesBusiness WireCyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician
4mo agoBIAF BIAFWbioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy CellsBusiness WireResearch suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at 2026 RNA Therapeutics Symposium June 24-26 bioAffinity Technologies,
4mo agoBIAF BIAFWbioAffinity Technologies Announces Closing of $3.2 Million OfferingBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced the
4mo agoBIAF BIAFWbioAffinity Technologies Announces Pricing of $3.2 Million OfferingBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced
5mo agoBIAF BIAFWbioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. VeteransBusiness WireExpert panel will share real-world case studies to demonstrate how mobile CT screening, noninvasive CyPath® Lung testing, and comprehensive functional lung imaging can reduce cost while improving access, early
5mo agoBIAF BIAFWMultidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy WebinarBusiness WireInterventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices CyPath® Lung has demonstrated the ability to aid
5mo agoBIAF BIAFWbioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung TechnologyBusiness WireStrong intellectual property portfolio helps build shareholder value Patent strategy protects CyPath® Lung's flow cytometry-driven diagnostic approach in international markets bioAffinity Technologies, Inc.
6mo agoBIAF BIAFWbioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026Business WireCyPath® Lung unit sales in April increased nearly 300% compared to April 2025 Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical use Noninvasive
6mo agoBIAF BIAFWbioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® LungBusiness WireCyPath® Lung cancer diagnostic unit sales rise 146% year-over-year Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath® Lung
6mo agoBIAF BIAFWbioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and TreatmentBusiness WireCollaboration with nation's largest military medical center focuses on bioAffinity Technologies' pipeline of solutions to address debilitating respiratory diseases Study to explore the potential for proprietary flow
7mo agoBIAF BIAFWNew Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary BiopsyBusiness WireStandard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary nodule CyPath® Lung test affirmed physician's assessment that the nodule could be inflammation, not
7mo agoBIAF BIAFWbioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16Business WireInvitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, to
7mo agoBIAF BIAFWbioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026Business WireNoninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors Flow cytometry+AI
7mo agoBIAF BIAFWbioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary PracticeBusiness WirePanel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First of "CyPath® Lung in Practice" webinar series focuses on
8mo agoBIAF BIAFWNew Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive ProceduresBusiness WireCyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung "Unlikely Malignancy" result supported physician's decision to wait before ordering an
8mo agoBIAF BIAFWbioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® LungBusiness WireLaboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99%
8mo agoBIAF BIAFWbioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer DiagnosticBusiness WireStudy to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences
8mo agoBIAF BIAFWbioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma PatientsBusiness WirePoster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research demonstrates the technology's ability to identify drug
8mo agoBIAF BIAFWbioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer TestBusiness WireValidating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive
8mo agoBIAF BIAFWNew Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung CancerBusiness WireCyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a low-dose CT
8mo agoBIAF BIAFWClinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case StudyBusiness WireNoninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters Case study highlights how CyPath® Lung reduces
9mo agoBIAF BIAFWbioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory BoardBusiness WireAdvisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a
11mo agoBIAF BIAFWbioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer RoundtableBusiness WirebioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD,
12mo agoBIAF BIAFWbioAffinity Technologies Reports Third Quarter 2025 Financial ResultsBusiness WireCompany achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on providing noninvasive, accurate
1y agoBIAF BIAFWbioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test VolumeBusiness WireOctober test volume 111% more than 2025 year-to-date monthly average bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung
1y agoBIAF BIAFWbioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung DiseasesBusiness WireAustralian patent strengthens global patent portfolio bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company's